Table A.11.
Univariate and multivariate analyses of factors associated with non-completion of study follow-up (n = 506) compared to those who completed 80% of study follow-up (n = 5812) in the North American region: Cox proportional hazard model (n = 6318)
| Non-completion of follow-up % | Univariate HR (95%CI) | Multivariate aHR (95%CI) | |
|---|---|---|---|
| Regimen* | |||
| 3HP-DOT (n = 3254) | 7.5 | Reference | |
| 9H-SAT (n = 3064) | 8.6 | 1.1 (0.96–1.37) | |
| Age, years (median = 37) | |||
| <37 (n = 3048) | 9.4 | 1.4(1.18–1.68) | 1.5 (1.28–1.86) |
| ⩾37 (n = 3270) | 6.7 | Reference | Reference |
| Sex | |||
| Female (n = 2838) | 6.1 | Reference | |
| Male (n = 3480) | 9.6 | 1.6 (1.33–1.92) | |
| Race | |||
| White (n = 3530) | 8.4 | Reference | Reference |
| Black (n = 1642) | 8.7 | 1.1 (0.86–1.28) | 1.0 (0.79–1.26) |
| Asian (n = 888) | 5.5 | 0.7 (0.48–0.88) | 0.6 (0.42–0.82) |
| Other (n = 258)† | 7.4 | 0.9 (0.55–1.39) | 0.8 (0.51–1.39) |
| Ethnicity | |||
| Non-Hispanic (n = 3668) | 7.4 | Reference | |
| Hispanic (n = 2650) | 8.9 | 1.2 (1.01–1.43) | |
| HIV status | |||
| Negative (n = 3142) | 7.9 | Reference | |
| Positive (n = 148) | 7.4 | 1.0 (0.52–1.74) | |
| Unknown (n = 3028) | 8.2 | 1.0 (0.87–1.24) | |
| Country of origin | |||
| Non-US (n = 3799) | 8.7 | Reference | Reference |
| US (n = 2519) | 7.0 | 0.8 (0.67–0.96) | 0.6 (0.44–0.71) |
| Educational level | |||
| ⩽8th grade (n = 1145) | 9.6 | 1.6 (1.19–2.17) | |
| 9th grade, some college (n = 3997) | 8.1 | 1.4 (1.05–1.75) | |
| College or higher (n = 1176) | 6.0 | Reference | |
| Incarceration‡ | |||
| No (n = 5925) | 7.6 | Reference | |
| Yes (n = 393) | 13.7 | 1.9 (1.41–2.48) | 1.4 (1.04–2.02) |
| Unemployed | |||
| No (n = 5534) | 7.9 | Reference | |
| Yes (n = 784) | 8.8 | 1.1 (0.87–1.45) | |
| Homeless§ | |||
| No (n = 5815) | 7.5 | Reference | Reference |
| Yes (n = 503) | 14.3 | 2.0 (1.54–2.54) | 2.1 (1.55–2.95) |
| Alcohol consumption¶ | |||
| No (n = 2909) | 6.7 | Reference | |
| Use (n = 2925) | 8.6 | 1.3 (1.07–1.56) | |
| Abuse (n = 484) | 12.2 | 1.9 (1.40–2.51) | |
| Injection drug use | |||
| No (n = 6052) | 7.9 | Reference | |
| Yes (n = 266) | 9.8 | 1.3 (0.85–1.86) | |
| Chronic liver disease (cirrhosis) | |||
| No (n = 6068) | 8.1 | Reference | |
| Yes (n = 250) | 6.0 | 0.7 (0.45–1.25) | |
| Current smoker | |||
| No (n = 4394) | 6.8 | Reference | Reference |
| Yes (n = 1924) | 10.8 | 1.6 (1.37–1.95) | 1.6 (1.31–1.96) |
| Methadone treatment | |||
| No (n = 6182) | 8.0 | Reference | |
| Yes (n = 136) | 7.4 | 0.9 (0.49–1.73) | |
| Pregnancy | |||
| Not possible (n = 3970) | 9.0 | Reference | Reference |
| Female (n = 2243) | 6.6 | 0.7 (0.59–0.87) | 0.8 (0.65–0.97) |
| Pregnancy (n = 105) | 2.9 | 0.3 (0.10–0.97) | 0.3 (0.1–0.98 |
| Enrolling site# | |||
| Missing clinic visit** | |||
| No (n = 5906) | 7.7 | Reference | Reference |
| Yes (n = 412) | 12.6 | 1.7 (1.25–2.22) | 1.4 (1.03–1.85) |
3HP-DOT = 3 months of directly observed once-weekly RPT (maximum dose, 900 mg) plus INH (maximum dose, 900 mg); 9H-SAT = 9 months of daily self-administered INH (maximum dose, 300 mg).
Includes North American Indian and other participants in the United States and Canada.
History of living in a correctional institution for ⩾1 month prior to enrollment.
History of homelessness or living in a shelter or single room occupancy for ⩾6 months prior to enrollment.
Use: affirmative response to a question asking whether the participant ever drank alcoholic beverages. Abuse: score of ⩾2 on the CAGE (Cut down, Annoyed, Guilty, Eye-opener) questionnaire.
Enrolling site was analyzed after a random selection of the reference value; overall P < 0.001.
Missing at least one of the first three DOT visits for the 3HP-DOT regimen and at least one of the three monthly clinic visits for the 9H-SAT regimen, followed by a DOT or a monthly visit after the missing DOT/visit, respectively (includes those who did not receive any study dose).
Note: Body mass index was explored, but due to a lack of statistical significance and lack of a meaningful association with the outcome, it was not included in the table/analyses.
HR = hazard ratio; CI = confidence interval; aHR = adjusted HR; H, INH = isoniazid; P, RPT = rifapentine; DOT = directly observed therapy; SAT = self-administered treatment; HIV = human immunodeficiency virus.